A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis

A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis

Tenoxicam (20 mg/day) and piroxicam (20 mg/day) were compared in a double-blind, parallel group study over 4 weeks in 30 patients with ankylosing spondylitis. Both tenoxicam and piroxicam reduced spinal pain, but the improvement was greater with piroxicam. Tenoxicam and piroxicam were equally effect...

Description complète

Détails bibliographiques
Publié dans:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 4(1986), 7 vom: 11., Seite 457-62
Auteur principal: Bird, H A (Auteur)
Autres auteurs: Le Gallez, P, Astbury, C, Looi, D, Wright, V
Format: Article
Langue:English
Publié: 1986
Accès à la collection:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Sujets:Clinical Trial Comparative Study Controlled Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Thiazines Piroxicam 13T4O6VMAM tenoxicam Z1R9N0A399